NCT07210723招募中2 期
A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Kardigan, Inc.78 个研究点 分布在 10 个国家目标入组 332 人开始时间: 2026年2月13日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 332
- 试验地点
- 78
- 主要终点
- Part 1: Change from Baseline (Day 1) to Week 26 in left atrial function index in Cohort 1
研究概览
简要总结
The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs that are designed specifically to treat genetic or familial DCM.
The purpose of this study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood; this can happen for different reasons. Some people have DCM because of a change in a gene (called genetic DCM). Others may have DCM that runs in their family, even if no specific gene change is found (called familial DCM).
The main goals of the study are:
- To assess the effect of danicamtiv on cardiac function using echocardiogram.
- To evaluate the impact of danicamtiv on exercise capacity
- To evaluate the safety and tolerability of danicamtiv
Participants will:
- Take danicamtiv or placebo every day for approximately 6 months
- Visit the clinic about 12 times for initial evaluation, checkups, tests and follow up
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has a diagnosis of DCM due to probable disease-causing variants of MYH7, TTN, or other identified genetic DCM variants, or with familial DCM
- •Has New York Heart Association (NYHA) Class II-IV at Screening with stable symptoms for ≥1 month.
- •Has at least mild left ventricular enlargement (LVE) and has adequate acoustic windows to enable accurate TTEs according to the Echocardiography Core Laboratory.
- •Has a LVEF of ≤45%.
- •Is on stable doses of maximally tolerated standard-of-care heart failure (HF) therapies reflecting current guidelines for at least 4 weeks prior to the first visit.
- •Has DCM not attributed to substance abuse, amyloidosis, sarcoidosis, or any other secondary form of cardiomyopathy per the Investigator.
- •Can perform an upright cardiopulmonary exercise training (CPET) with a peak oxygen uptake (pV̇O2) of 80% or less of predicted for a healthy individual and respiratory exchange ratio (RER) of ≥1.05
排除标准
- •Has heart failure with reduced ejection (HFrEF) caused primarily by ischemic heart disease, chronic valvulopathy, or another condition, as determined by the Investigator.
- •Recent (<90 days) clinically significant cardiac events, including acute coronary syndrome, hemodynamically significant epicardial coronary disease (per Investigator), coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]), or hospitalization for heart failure/intravenous (IV) diuretic use.
- •Presence of disqualifying cardiac rhythms that might interfere with reliable echocardiographic measurements of left ventricle (LV) function, as determined by the Investigator including: (a) inadequately rate-controlled atrial fibrillation, (b) ectopic beats (atrial, junctional or ventricular) of sufficient frequency (e.g. > 10% of total beats) that the participant's cardiac rhythm is irregular potentially interfering with reliable echocardiographic measurements of LV function.
- •Unstable or untreated severe ventricular arrythmia (eg, ventricular tachycardia or ventricular fibrillation).
- •History of malignancy of any type within 5 years prior to Screening
- •Severe renal insufficiency (defined at the time of Screening as current estimated glomerular filtration rate [eGFR] <15 mL/min/1.73m2 by simplified Modification of Diet in Renal Disease equation [sMDRD]).
- •History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the Investigator or Sponsor, would pose a risk to participant safety or interfere with the study evaluation
- •History of heart transplantation or anticipated heart transplantation in the next 6 months.
- •Ongoing or anticipated advanced cardiac interventions, including chronic IV inotropic therapy, planned cardiac resynchronization therapy (CRT) or major surgery, or current/anticipated ventricular assist device placement within 6 months
- •Clinically significant laboratory abnormalities at Screening
研究组 & 干预措施
danicamtiv
Experimental
干预措施: danicamtiv (Drug)
placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Part 1: Change from Baseline (Day 1) to Week 26 in left atrial function index in Cohort 1
时间窗: 26 weeks
Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in Cohort 1
时间窗: 26 weeks
次要结局
- Part 1: Change from Baseline (Day 1) to Week 26 in peak VO2(26 weeks)
- Part 1: Association between response in left ventricular global longitudinal strain and/or left atrial function index after 2 weeks of active treatment with placebo-adjusted Week 26 response in peak VO2(26 weeks)
- Part 1 and 2: Change from Baseline (Day 1) to Week 26 in Kansas City Cardiomyopathy Questionnare (KCCQ-23) Clinical Summary Score(26 weeks)
- Part 1: Proportion of participants from Baseline (Day 1) to Week 26 who achieve at least a one-class improvement in New York Heart Association (NYHA) class(26 weeks)
- Part 1: Change from Baseline (Day 1) to Week 26 in left atrial function index in overall population(26 weeks)
- Part 1 and 2: Change from Baseline (Day 1) to Week 26 in left ventricular ejection fraction(26 weeks)
- Part 1 and 2: Change from Baseline (Day 1) to Week 26 in ventilatory efficiency(26 weeks)
- Part 2: Change from Baseline (Day 1) to Week 26 in left atrial function index(26 weeks)
- Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in the responder subgroup(26 weeks)
- Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in overall population(26 weeks)
- Part 1 and 2: Change from Baseline (Day 1) to Week 26 in left ventricular global longitudinal strain(26 weeks)
- Part 1 and 2: Percent change from Baseline (Day 1) to Week 26 in NT-proBNP concentrations(26 weeks)
- Part 1 and 2: Characterization of peak (Cmax) of danicamtiv(20 weeks)
- Part 1 and 2: Characterization of trough (Cmin) plasma concentrations of danicamtiv(20 weeks)
研究者
研究点 (78)
Loading locations...
相似试验
终止
1 期
Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy AdultsHealthyNCT01345864Pfizer88
已完成
2 期
An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 ChallengeDengueNCT05048875National Institute of Allergy and Infectious Diseases (NIAID)56
Unknown
1 期
Safety and Activity of ORE1001 in Subjects With Ulcerative ColitisMild to Moderate Ulcerative ColitisNCT01039597Ore Pharmaceuticals, Inc.50
已完成
2 期
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)SchizophreniaParanoid SchizophreniaNCT00482430Merck Sharp & Dohme LLC50
招募中
2 期
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.Carcinoma, HepatocellularNCT06349980Shanghai Henlius Biotech117